Telotristat (High-Dose) for Neuroendocrine Tumors

"Clinicaltrials.gov denotes that this trial is actively searching for participants, with the original posting on July 19th 2021 and the latest edit made on November 10th 2022."

"According to the inclusion criteria, this trial only includes people between 18 and 100 years old. There are 15 clinical trials for minors below 18 and 167 studies that target patients over 65 years of age."

"This medical trial requires participants to meet two prerequisites: they must have previously failed a systemic cancer treatment for their neuroendocrine tumors, and possess an ECOG performance status of 2 or lower. These conditions apply to all 70 individuals aged 18-100 who are being recruited."

"Affirmative. According to clinicaltrials.gov, this research study is currently seeking participants. It was first published on July 19th 2021 and last modified on November 10th 2022 with the intent of enrolling 70 individuals at one site only."

"Currently, 4 clinical trials are underway for Telotristat (High-Dose). One of these is at Phase 3. While the majority of studies occur in Houston, Texas; 6 sites across the US are running research with this drug."

"The drug Telotristat (High-Dose) has been assigned a safety score of 2, as it is currently undergoing Phase 2 trials where limited data exists in regards to its efficacy but some evidence supports its security."